Kraków-based Bitspiration VC launches €50m target Biotech III

The Krakow-based manager Bitspiration VC has launched the fund “Bitspiration Biotech III” with a target volume of 50 million euros. On November 10, 2026, Bitspiration informed Vestbee that an initial closing of 15 to 20 million euros was expected for November.

According to Vestbee and mambiznes, the fund plans to invest between 250,000 and 4 million euros per company, targeting initial equity stakes of 2% to 15%. The fund aims to support up to 25 startups – primarily in the pre-seed and seed phases, supplemented by selected Series A financing rounds. The focus is on biotech platform technologies, particularly in the areas of drug discovery, therapeutics and diagnostics, synthetic biology, and advanced biomaterials. As reported by pb.pl, the fund’s geographic focus is on Poland and Central and Eastern Europe; it also highlights hematology, oncology, and rare or hereditary diseases as key areas of interest.

Dr. Sebastian Soluch has joined the team as a General Partner and co-manages the fund alongside Andrzej Targosz, a founding partner of Bitspiration. According to pb.pl, Soluch brings over 20 years of experience in the pharmaceutical industry. Vestbee identifies several investors, including Marcin Żukowski, co-founder of Snowflake, and Tomasz Onyszko, co-founder of Predica. According to pb.pl, a significant portion of the capital comes from investors who also participated in the firm’s previous fund.

Founded in 2016, Bitspiration has historically invested broadly across the technology sector, rather than focusing exclusively on biotech. According to press reports, the first fund achieved a “cash-on-cash” return (DPI) of 1.7 times the invested capital. For the second fund, a total value (TVPI) of an estimated 2.16 times the invested capital is reported.